PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $1.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $1.09M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $992.00K.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $385.00K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $472.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $992.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $385.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $472.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-04 |
| 2025-03-31 | $1.19M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $3.40M 10-K · filed 2025-02-27 |
| 2024-09-30 | $11.17M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $24.39M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $42.91M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $117.70M 10-K · filed 2024-02-22 |
| 2023-09-30 | $209.16M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $388.38M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $236.04M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $344.88M 10-K · filed 2023-02-28 |
| 2022-09-30 | $374.08M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $83.45M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $162.88M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $260.13M 10-K · filed 2022-02-25 |
| 2021-09-30 | $439.88M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $288.03M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $77.13M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $4.51M 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.99M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $2.41M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.63M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $11.28M 10-K · filed 2020-03-03 |
| 2019-09-30 | $720.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $2.35M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $3.26M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $2.17M 10-K · filed 2019-03-15 |
| 2018-09-30 | $3.76M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $4.88M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |